128,180 Shares in BWX Technologies, Inc. $BWXT Bought by Legal & General Group Plc

Legal & General Group Plc purchased a new stake in shares of BWX Technologies, Inc. (NYSE:BWXT) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 128,180 shares of the technology company’s stock, valued at approximately $24,950,000. Legal & General Group Plc owned approximately 0.14% of BWX Technologies at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Cannell & Spears LLC lifted its stake in shares of BWX Technologies by 4.0% in the first quarter. Cannell & Spears LLC now owns 1,312 shares of the technology company’s stock valued at $251,000 after buying an additional 50 shares in the last quarter. Wedbush Securities Inc. raised its holdings in shares of BWX Technologies by 4.3% in the 4th quarter. Wedbush Securities Inc. now owns 1,263 shares of the technology company’s stock worth $218,000 after acquiring an additional 52 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its position in BWX Technologies by 1.0% in the 4th quarter. Oppenheimer Asset Management Inc. now owns 5,448 shares of the technology company’s stock valued at $942,000 after acquiring an additional 54 shares in the last quarter. Guggenheim Capital LLC increased its holdings in BWX Technologies by 2.2% during the 4th quarter. Guggenheim Capital LLC now owns 2,598 shares of the technology company’s stock worth $449,000 after purchasing an additional 55 shares in the last quarter. Finally, Private Advisor Group LLC raised its stake in shares of BWX Technologies by 2.4% in the first quarter. Private Advisor Group LLC now owns 2,847 shares of the technology company’s stock worth $582,000 after purchasing an additional 67 shares during the last quarter. Institutional investors and hedge funds own 94.39% of the company’s stock.

Analysts Set New Price Targets

BWXT has been the topic of several analyst reports. JPMorgan Chase & Co. assumed coverage on BWX Technologies in a research report on Monday, July 27th. They set an “overweight” rating and a $230.00 target price on the stock. Zacks Research lowered shares of BWX Technologies from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Seaport Research Partners upgraded BWX Technologies from a “neutral” rating to a “buy” rating and set a $245.00 target price on the stock in a research note on Monday, June 22nd. Wall Street Zen downgraded BWX Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, BTIG Research reiterated a “buy” rating and set a $235.00 price target on shares of BWX Technologies in a report on Tuesday, August 4th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, BWX Technologies presently has an average rating of “Moderate Buy” and a consensus price target of $224.20.

BWX Technologies Price Performance

BWX Technologies stock opened at $153.12 on Friday. The company has a debt-to-equity ratio of 1.51, a current ratio of 2.40 and a quick ratio of 2.33. BWX Technologies, Inc. has a one year low of $147.74 and a one year high of $241.82. The firm has a market capitalization of $14.03 billion, a P/E ratio of 39.67, a PEG ratio of 2.39 and a beta of 0.76. The business has a fifty day moving average price of $175.83 and a 200-day moving average price of $195.80.

BWX Technologies (NYSE:BWXT) last announced its quarterly earnings results on Monday, August 3rd. The technology company reported $1.07 earnings per share for the quarter, beating the consensus estimate of $1.04 by $0.03. The firm had revenue of $901.62 million for the quarter, compared to analysts’ expectations of $902.41 million. BWX Technologies had a return on equity of 30.83% and a net margin of 10.11%.The company’s revenue was up 18.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.02 earnings per share. BWX Technologies has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, equities research analysts forecast that BWX Technologies, Inc. will post 4.75 EPS for the current year.

BWX Technologies Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 4th. Stockholders of record on Tuesday, August 18th will be given a dividend of $0.27 per share. The ex-dividend date is Tuesday, August 18th. This represents a $1.08 annualized dividend and a dividend yield of 0.7%. BWX Technologies’s dividend payout ratio (DPR) is 27.98%.

Insider Buying and Selling

In other BWX Technologies news, CEO Rex D. Geveden sold 10,000 shares of BWX Technologies stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $172.50, for a total transaction of $1,725,000.00. Following the completion of the sale, the chief executive officer owned 192,491 shares of the company’s stock, valued at $33,204,697.50. The trade was a 4.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.60% of the stock is currently owned by corporate insiders.

BWX Technologies Profile

BWX Technologies, Inc (NYSE: BWXT) is a specialized supplier of nuclear components and services, primarily serving the U.S. government and commercial markets. The company’s core expertise lies in the design, fabrication and servicing of nuclear propulsion systems for the U.S. Navy, where it supports the maintenance and overhaul of naval nuclear reactors. In addition to defense applications, BWXT develops small modular reactors (SMRs), nuclear fuel and related technologies for non‐defense power generation, offering scalable solutions to meet evolving energy and industrial demands.

Beyond propulsion and power systems, BWXT is a leading producer of medical radioisotopes used in diagnostic imaging and cancer treatment.